Journal Article10.7150/ijms.88481
Developing a Prognostic Model for Primary Biliary Cholangitis Based on a Random Survival Forest Model
Xinxin Fu,Ya-Qi Song,Jiale Lin,Yi Wang,Wei-dan Wu,Jin-bang Peng,Li-ping Ye,Kai Chen,Shao-wei Li +8 more
TL;DR: A prognostic model for PBC-associated cirrhosis patients is constructed using a random survival forest model, which accurately stratified patients into low- and high-risk groups, leading to improved outcomes for high-risk patients.
read more
Abstract: Background: Primary biliary cholangitis (PBC) is a rare autoimmune liver disease with few effective treatments and a poor prognosis, and its incidence is on the rise. There is an urgent need for more targeted treatment strategies to accurately identify high-risk patients. The use of stochastic survival forest models in machine learning is an innovative approach to constructing a prognostic model for PBC that can improve the prognosis by identifying high-risk patients for targeted treatment. Method: Based on the inclusion and exclusion criteria, the clinical data and follow-up data of patients diagnosed with PBC-associated cirrhosis between January 2011 and December 2021 at Taizhou Hospital of Zhejiang Province were retrospectively collected and analyzed. Data analyses and random survival forest model construction were based on the R language. Result: Through a Cox univariate regression analysis of 90 included samples and 46 variables, 17 variables with p-values <0.1 were selected for initial model construction. The out-of-bag (OOB) performance error was 0.2094, and K-fold cross-validation yielded an internal validation C-index of 0.8182. Through model selection, cholinesterase, bile acid, the white blood cell count, total bilirubin, and albumin were chosen for the final predictive model, with a final OOB performance error of 0.2002 and C-index of 0.7805. Using the final model, patients were stratified into high-and low-risk groups, which showed significant differences with a P value <0.0001. The area under the curve was used to evaluate the predictive ability for patients in the first, third, and fifth years, with respective results of 0.9595, 0.8898, and 0.9088. Conclusion: The present study constructed a prognostic model for PBC-associated cirrhosis patients using a random survival forest model, which accurately stratified patients into low-and high-risk groups. Treatment strategies can thus be more targeted, leading to improved outcomes for high-risk patients.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
References
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Frederik Nevens,Pietro Andreone,Giuseppe Mazzella,Simone I. Strasser,Christopher L. Bowlus,Pietro Invernizzi,J.P.H. Drenth,Paul J. Pockros,Jaroslaw Regula,Ulrich Beuers,Michael Trauner,David Jones,Annarosa Floreani,Simon Hohenester,Velimir A. Luketic,Mitchell L. Shiffman,K.J. van Erpecum,Victor Vargas,Catherine Vincent,Gideon M. Hirschfield,Hemant Shah,Bettina E. Hansen,Keith D. Lindor,Hanns-Ulrich Marschall,Kris V. Kowdley,R. Hooshmand-Rad,T. Marmon,S. Sheeron,R. Pencek,Leigh MacConell,Mark Pruzanski,David Shapiro +31 more
TL;DR: Obeticholic acid administered with ursodiol or as monotherapy for 12 months in patients with primary biliary cholangitis resulted in decreases from baseline in alkaline phosphatase and total bilirubin levels that differed significantly from the changes observed with placebo.
Artificial Intelligence and Machine Learning in Clinical Medicine, 2023
30 Mar 2023
TL;DR: In this paper , the authors describe the history of artificial intelligence in medicine; the use of AI in image analysis, identification of disease outbreaks, and diagnosis; and the usage of chatbots.
546
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study
Willem J Lammers,Henk R. van Buuren,Gideon M. Hirschfield,Harry L.A. Janssen,Pietro Invernizzi,Andrew Mason,Cyriel Y. Ponsioen,Annarosa Floreani,Christophe Corpechot,Marlyn J. Mayo,Pier Maria Battezzati,Albert Parés,Frederik Nevens,Andrew K. Burroughs,Kris V. Kowdley,Palak J. Trivedi,Teru Kumagi,Teru Kumagi,Angela M. Cheung,Ana Lleo,Mohamad Imam,Kirsten Boonstra,Nora Cazzagon,I. Franceschet,Raoul Poupon,Llorenç Caballería,G. Pieri,Pushpjeet Kanwar,Keith D. Lindor,Keith D. Lindor,Bettina E. Hansen +30 more
TL;DR: Levels of alkaline phosphatase and bilirubin can predict outcomes (liver transplantation or death) of patients with PBC and might be used as surrogate end points in therapy trials.
447
A review on machine learning approaches and trends in drug discovery.
Paula Carracedo-Reboredo,Jose Liñares-Blanco,Nereida Rodriguez-Fernandez,Francisco Cedrón,Francisco J. Novoa,Adrian Carballal,Victor Maojo,Alejandro Pazos,Carlos Fernandez-Lozano +8 more
TL;DR: In this paper, a review of the state of the art in machine learning for drug discovery is presented, focusing mainly on the methods used to model the molecular data, as well as the biological problems addressed and the Machine Learning algorithms used for drugs discovery in recent years.
292